Troubleshooting Report - CE-SDS: baseline disturbances, peak area repeatability and the presence of ghost peaks

Troubleshooting CE-SDS: baseline disturbances, peak area repeatability and the presence of ghost peaks

Workshop Leaders: Cari Sänger-van de Griend¹, Timothy Blanc²

Scribes: Jiann Kae Luo³, Bernd Moritz⁴, Joop Waterval⁵, Fabian Suriano⁶

Compilers: Jiann Kae Luo, Cari Sänger-van de Griend

1. Kantisto BV, Baarn, the Netherlands; Uppsala University, Div. of Pharmaceutical Analytical Chemistry, Uppsala, Sweden; ACROSS, University of Tasmania, Hobart, Australia
2. Eli Lilly and Company, Branchburg, NY, USA
3. Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
4. F. Hoffmann-La Roche Ltd., Basel, Switzerland
5. Merck, Sharp & Dohme, Oss, The Netherlands
6. ANALIS s.a./n.v., Suralee, Belgium